{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:02:27Z","timestamp":1794589347697,"version":"4.9.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.eururo.2013.06.043","type":"journal-article","created":{"date-parts":[[2013,7,2]],"date-time":"2013-07-02T18:15:28Z","timestamp":1372788928000},"page":"664-671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Protective Effect of a \u03b23-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder Ischemia"],"prefix":"10.1016","volume":"64","author":[{"given":"Norifumi","family":"Sawada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nomiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandy","family":"Hood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Koslov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Zarifpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Erik","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.eururo.2013.06.043_bib0005","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0010","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.eururo.2012.08.047","article-title":"EAU guidelines on assessment and nonsurgical management of urinary incontinence","volume":"62","author":"Lucas","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0015","first-page":"CD005429","article-title":"Which anticholinergic drug for overactive bladder symptoms in adults","author":"Madhuvrata","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2013.06.043_bib0020","doi-asserted-by":"crossref","unstructured":"Andersson KE, Martin N, Nitti V. Selective \u03b23-adrenoceptor agonists in the treatment of the overactive bladder. J Urol. In press. http:\/\/dx.doi.org\/10.1016\/j.juro.2013.02.104.","DOI":"10.1016\/j.juro.2013.02.104"},{"key":"10.1016\/j.eururo.2013.06.043_bib0025","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0030","doi-asserted-by":"crossref","unstructured":"Chapple CR, Dvorak V, Radziszewski P, et al., Dragon Investigator Group. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J. In press. http:\/\/dx.doi.org\/10.1007\/s00192-013-2042-x.","DOI":"10.1007\/s00192-013-2042-x"},{"key":"10.1016\/j.eururo.2013.06.043_bib0035","doi-asserted-by":"crossref","unstructured":"Chapple CR, Amarenco G, L\u00f3pez Aramburu MA, et al., BLOSSOM Investigator Group. A proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurourol Urodyn. In press. http:\/\/dx.doi.org\/10.1002\/nau.22373","DOI":"10.1002\/nau.22373"},{"key":"10.1016\/j.eururo.2013.06.043_bib0040","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a \u03b23-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0045","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a \u03b23-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2006.01.031","article-title":"The association between vascular risk factors and lower urinary tract symptoms in both sexes","volume":"50","author":"Ponholzer","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0055","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1464-410X.2008.07587.x","article-title":"Association of lower urinary tract symptoms and chronic ischaemia of the lower urinary tract in elderly women and men: assessment using colour Doppler ultrasonography","volume":"102","author":"Pinggera","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.043_bib0060","doi-asserted-by":"crossref","unstructured":"Uzun H, Ci\u00e7ek Y, Kocaman SA, Durako\u011flugil ME, Zorba OU. Increased pulse-wave velocity and carotid intima-media thickness in patients with lower urinary tract symptoms. Scand J Urol. http:\/\/dx.doi.org\/10.3109\/21681805.2013.780185","DOI":"10.3109\/21681805.2013.780185"},{"key":"10.1016\/j.eururo.2013.06.043_bib0065","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/nau.21073","article-title":"The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat","volume":"31","author":"Nomiya","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.06.043_bib0070","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/nau.21191","article-title":"Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia","volume":"31","author":"Nomiya","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2013.06.043_bib0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/978-1-4615-4737-2_18","article-title":"Pathways for relaxation of detrusor smooth muscle","volume":"462","author":"Andersson","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejphar.2005.06.029","article-title":"Involvement of cyclic AMP-dependent and -independent mechanisms in the relaxation of rat detrusor muscle via beta-adrenoceptors","volume":"518","author":"Uchida","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0085","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","article-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors","volume":"377","author":"Frazier","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrurol.2011.194","article-title":"Role of potassium ion channels in detrusor smooth muscle function and dysfunction","volume":"9","author":"Petkov","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0095","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1172\/JCI116922","article-title":"Restoration of the cAMP second messenger pathway enhances cardiac preservation for transplantation in a heterotopic rat model","volume":"92","author":"Pinsky","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2013.06.043_bib0100","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0041-1345(98)01907-1","article-title":"Preservation of livers from non-heart-beating donors: modulation of cAMP signal and organ viability by glucagon","volume":"31","author":"Minor","year":"1999","journal-title":"Transplant Proc"},{"key":"10.1016\/j.eururo.2013.06.043_bib0105","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/00007890-200110150-00006","article-title":"The enhancement of endogenous cAMP with pituitary adenylate cyclase-activating polypeptide protects rat kidney against ischemia through the modulation of inflammatory response","volume":"72","author":"Riera","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.eururo.2013.06.043_bib0110","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/00005392-200101000-00072","article-title":"The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs","volume":"165","author":"Greenland","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2013.06.043_bib0115","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1464-410x.2000.00611.x","article-title":"The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder","volume":"85","author":"Greenland","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.043_bib0120","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.RES.69.3.571","article-title":"ATP-regulated K+ channels protect the myocardium against ischemia\/reperfusion damage","volume":"69","author":"Cole","year":"1991","journal-title":"Circulation Res"},{"key":"10.1016\/j.eururo.2013.06.043_bib0125","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1074360","article-title":"Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane","volume":"298","author":"Xu","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.eururo.2013.06.043_bib0130","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1734-1140(11)70413-3","article-title":"Cytoprotective action of the potassium channel opener NS1619 under conditions of disrupted calcium homeostasis","volume":"63","author":"Chmielewska","year":"2011","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.eururo.2013.06.043_bib0135","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.eururo.2013.06.043_bib0140","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1111\/j.1464-410X.2012.11240.x","article-title":"Modulation of non-voiding activity by the muscarinergic antagonist tolterodine and the \u03b2(3)-adrenoceptor agonistmirabegron in conscious rats with partial outflow obstruction","volume":"110","author":"Gillespie","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.06.043_bib0145","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.eururo.2012.08.056","article-title":"Effects of mirabegron, a novel beta3-adrenoceptor agonist, on primary bladder afferent activity and bladder microcontractions in rats compared with the effects of oxybutynin","volume":"62","author":"Aizawa","year":"2012","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813006581?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813006581?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,14]],"date-time":"2018-10-14T17:51:52Z","timestamp":1539539512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813006581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0302283813006581"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.06.043","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protective Effect of a \u03b23-Adrenoceptor Agonist on Bladder Function in a Rat Model of Chronic Bladder Ischemia","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2013.06.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}